Business Context and Reporting Period
This Form 6-K filing by Novo Nordisk A/S, dated October 14, 2024, reports on the company's ongoing share repurchase programme. Novo Nordisk is a leading global healthcare company headquartered in Denmark, employing approximately 69,000 people across 80 countries. The filing details transactions executed under a specific sub-programme initiated on August 7, 2024, which is part of a broader 12-month repurchase plan authorized to spend up to DKK 20 billion starting February 6, 2024.
Key Financial Metrics
The filing focuses exclusively on capital allocation activities regarding share buybacks rather than operational financial performance.
- Share Repurchase Programme (August 7 - November 4, 2024): Authorized up to DKK 2.4 billion.
- Transactions Reported (Oct 7 - Oct 11, 2024): 237,000 B shares purchased.
- Accumulated Repurchases (Current Sub-programme): 2,066,522 B shares for a total value of DKK 1,801,045,066.
- Accumulated Repurchases (Total Programme since Feb 6, 2024): 13,133,648 B shares at an average price of DKK 877.80, totaling DKK 11,528,751,116.
- Treasury Shares: The company holds 14,462,279 B shares as treasury shares, representing 0.3% of total share capital.
The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity metrics.
Material Changes
The primary material change reported is the execution of share repurchases during the week of October 7 to October 11, 2024. The average purchase price for these specific transactions ranged from DKK 794.12 to DKK 811.88. Consequently, the total value of shares repurchased under the current sub-programme increased from DKK 1,611,318,553 to DKK 1,801,045,066.
Guidance, Outlook, and Risks
Outlook: Novo Nordisk expects to continue repurchasing B shares up to the total limit of DKK 20 billion during the 12-month period beginning February 6, 2024. As of October 11, 2024, approximately DKK 11.5 billion of this authorization has been utilized.
Risks and Contingencies: The filing does not disclose new risks or contingencies. It notes that the repurchase programme is conducted in accordance with the EU Market Abuse Regulation (MAR) and Safe Harbour Rules.
Investor Verification Checklist
- Verify the remaining authorization under the DKK 20 billion total programme (approximately DKK 8.5 billion remaining as of Oct 11, 2024).
- Confirm the current market price of Novo Nordisk B shares relative to the recent average repurchase price of DKK 877.80.
- Review the full transaction details on novonordisk.com for daily execution data.
- Check the total share capital count (4,465,000,000 shares) to understand the dilution impact of treasury shares.